VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. "At Absci, we're constantly pushing the boundaries of innovation to bring better biologics to patients faster," said Sean McClain, Founder and CEO of Absci. "By combining Absci's AI de novo design expertise with Owkin's world-class predictive AI target discovery technology, we have a unique opp

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. AMD will also make a $20 million investment in Absci, structured as a private investment in public equity (PIPE), underscoring the growing demand for innovative AI applications in drug discovery. The strategic partnership supports Absci's mission of creating better biologics for patients, faster by providing optimized AI solutions for complex biol

VANCOUVER, Wash. and BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, and Invetx, a pioneer in protein-based therapeutics for animal health, today announced a strategic partnership to harness Absci's AI Drug Creation models to create an innovative Half-Life Extension (HLE) platform for animal health applications. "Absci has built a leading generative AI Drug Creation platform for therapeutic antibodies and we're excited to bring this expertise into animal health," said Sean McClain, Founder and CEO of Absci. "We look forward to working with Invetx to address the large underserved animal health market by leveraging

VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Absci management is scheduled to present on Wednesday, January 15th at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company's investor relations website at: investors.absci.com. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologi

Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development for androgenic alopecia Leading AI platform demonstrated breakthrough in successful de novo design of antibody targeting previously difficult-to-drug epitope in the HIV "caldera" region VANCOUVER, Wash. and NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced updates and progress across its internal pipeline of proprietary Drug Creation programs, as well as new breakthroughs demonstrated by Absci's AI Integrated Drug Creation™ platform. Absci leadership and a series of distinguished

VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY. Absci's Founder & CEO Sean McClain is scheduled to participate in a panel discussion titled "The Promise of AI in Drug Development" on Thursday, December 5th at 2:00 p.m. Eastern Time. Interested parties may contact their Piper Sandler representative to request registration details for this live event. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab te

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody using generative AI VANCOUVER, Wash. and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2024. "The recent progress we have made across our portfolio of internal and partnered programs illustrates our commitment to delivering results," said Sean McClain, Founder and CEO. "Through achieving a milestone in our collaboration with Ast

VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City. The program will begin at 9:00 a.m. Eastern Time and feature presentations from members of Absci's leadership team as well as guest speakers, followed by an interactive Q&A session. The program is expected to conclude at approximately 12:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of Absci's R&D Day on the company's investor relations website at: investors.absci.com. About Absci Absci is a data-first genera

VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) a data-first generative AI drug creation company, and Twist Bioscience Corporation (NASDAQ:TWST) a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today unveiled a collaboration to design a novel therapeutic using generative AI. "Bringing together two leaders in biotechnology innovation represents an opportunity to accelerate pharmaceutical R&D," said Absci Founder & CEO Sean McClain. "We are excited to strengthen our relationship with Twist and leverage the power of our shared platforms to bring better bio

VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. Truist Securities BioPharma Symposium (New York, NY)Hosting 1x1 meetings on Thursday, November 7 Guggenheim Securities Inaugural Healthcare Innovation Conference (Boston, MA)Fireside chat on Monday, November 11 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time, and hosting 1x1 meetings UBS Global Healthcare Conference (Rancho Palos Verdes, CA)Fireside chat on Wednesday, November 13 at 10:15 a.m. Eastern Time / 7:15 a.m. Pacific Time, and hosti

4 - Absci Corp (0001672688) (Issuer)

8-K - Absci Corp (0001672688) (Filer)

8-K - Absci Corp (0001672688) (Filer)

8-K - Absci Corp (0001672688) (Filer)

10-Q - Absci Corp (0001672688) (Filer)

8-K - Absci Corp (0001672688) (Filer)

8-K - Absci Corp (0001672688) (Filer)

10-Q - Absci Corp (0001672688) (Filer)

8-K - Absci Corp (0001672688) (Filer)

ARS - Absci Corp (0001672688) (Filer)

DEFA14A - Absci Corp (0001672688) (Filer)

4 - Absci Corp (0001672688) (Issuer)

4 - Absci Corp (0001672688) (Issuer)

4 - Absci Corp (0001672688) (Issuer)

4 - Absci Corp (0001672688) (Issuer)

4 - Absci Corp (0001672688) (Issuer)

4 - Absci Corp (0001672688) (Issuer)

4 - Absci Corp (0001672688) (Issuer)

3 - Absci Corp (0001672688) (Issuer)

4 - Absci Corp (0001672688) (Issuer)

4 - Absci Corp (0001672688) (Issuer)

SC 13G - Absci Corp (0001672688) (Subject)

SC 13G/A - Absci Corp (0001672688) (Subject)

SC 13D/A - Absci Corp (0001672688) (Subject)

SC 13G/A - Absci Corp (0001672688) (Subject)

SC 13G - Absci Corp (0001672688) (Subject)

SC 13G/A - Absci Corp (0001672688) (Subject)

SC 13D/A - Absci Corp (0001672688) (Subject)

SC 13D/A - Absci Corp (0001672688) (Subject)

SC 13G/A - Absci Corp (0001672688) (Subject)

SC 13G/A - Absci Corp (0001672688) (Subject)

Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e

VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a

VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a generative AI drug creation company, today announced Meta Connectivity VP Dan Rabinovitsj as the newest member of its Board of Directors. With three decades of leadership in scaling technologies, innovating business models and growing companies, Mr. Rabinovitsj will provide strategic insights as Absci continues to scale its unprecedented combination of AI and wet lab capabilities to help create better biologics for patients, faster. "Absci has impressed me with their technology and data, together which have the potential to turn Absci's bold vision into reality: to create therapeutics at a

- Dr. Busch transitions from Absci's Board of Directors to Absci's Executive Leadership team -With a proven track record advancing drugs from discovery to market, Dr. Busch brings world-class R&D expertise to Absci's executive leadership team VANCOUVER, Wash. and NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data to design better therapeutics, faster, today announced the appointment of Andreas Busch, PhD, as Chief Innovation Officer, where he will be responsible for leading R&D, technical operations, and driving both Absci's internal and partner programs. As a f

VANCOUVER, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the appointment of Andreas Busch, PhD, to its Board of Directors. Dr. Busch is the former EVP and Chief Scientific Officer at Shire Plc and Head of Drug Discovery at Bayer and is currently Chief Scientific Officer at Cyclerion Therapeutics, Inc. He brings over twenty years of pharmaceutical industry executive experience in drug discovery R&D leadership positions. "I'm excited to have Dr. Busch join Absci's board and to be able to leverage his deep expert

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody using generative AI VANCOUVER, Wash. and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2024. "The recent progress we have made across our portfolio of internal and partnered programs illustrates our commitment to delivering results," said Sean McClain, Founder and CEO. "Through achieving a milestone in our collaboration with Ast

VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the

Released results from non-human primate studies for ABS-101, demonstrating 2-3x extended half-life as compared to antibodies in clinical development Entered into collaboration with Memorial Sloan Kettering Cancer Center to co-develop up to six novel oncology therapeutics VANCOUVER, Wash. and NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended June 30, 2024. "Our recent achievements demonstrate solid execution across all aspects of our business, as we continue to progress internal and partnered programs according to plan," said Sean McClain, Foun

VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the second quarter after market close on Wednesday, August 14, 2024. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, May 14, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for repl

Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI 10 new Active Programs in 2022, exceeding full-year guidance VANCOUVER, Wash. and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), the generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2022. "2022 was a transformational year for Absci that saw research collaborations with Merck and NVIDIA, and included continued strengthening of our platform, talent, and infrastructure, paving the way for an already-monumental 2023," said Sean McCl

Milestone achievement and progress continues in previously announced Merck collaboration Further strengthened executive leadership and Board of Directors VANCOUVER, Wash. and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2022. "Absci delivered a strong quarter of successful execution in partnered programs, technical breakthroughs, and continued strengthening of our organization," said Sean McClain, Founder and CEO. "During this past quarter, we demonstrated the powerful capabilities of our Integrated Drug Creation™ platform by leveragin

Exceeded annual Active Program guidance with ten programs signed year-to-date Executed strategic reorganization to extend cash runway into late-2025 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30, 2022. "As we pass the halfway point of 2022, our team continues to make excellent progress toward our stated objectives," said Sean McClain, founder and CEO. "Since becoming a public company one year ago, we have signed 13 discovery

VANCOUVER, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended March 31, 2022. "We've made great progress so far this year on all fronts - advancing existing partnered programs, embarking on new collaborations, and enhancing our technology platform," said Sean McClain, founder and CEO. "It's been especially exciting to share publicly some of our AI breakthroughs and progress toward fully in silico drug creation; we expect to continue this momentum both through our c

VANCOUVER, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter and full year ended December 31, 2021. "Our progress this quarter capped off a remarkable year for Absci from start to finish," said Sean McClain, Founder and CEO. "In the last few months alone, we announced collaborations with EQRx and Merck including six drug discovery programs in total. And earlier today we shared data around some of our groundbreaking AI models for therapeutic protein design and optimi